



Published in final edited form as:

Breast Cancer Res Treat. 2017 December ; 166(3): 793–808. doi:10.1007/s10549-017-4454-7.

Lymphedema, Musculoskeletal Events and Arm Function in Older Patients Receiving Adjuvant Chemotherapy for Breast Cancer (Alliance A171302)

Judith O. Hopkins¹, Jake Allred^{2,3}, Arti Hurria⁴, Aminah Jatoi³, Jacqueline M. Lafky^{2,3}, Harvey Cohen⁵, Clifford Hudis⁶, Eric Winer⁷, Jeanne Mandelblatt⁸, Ann Partridge⁷, Lisa Carey⁹, and Hyman B. Muss⁹

¹Novant Health Forsyth Medical Center, Winston-Salem, NC

²Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN

³Mayo, Clinic, Rochester, MN

⁴City of Hope, Duarte, CA

⁵Duke Cancer Institute, Duke University Medical Center, Durham, NC

⁶Memorial Sloan Kettering Cancer Center, New York, NY

⁷Dana-Farber/Partners CancerCare, Boston, MA

⁸MedStar Georgetown University Hospital, Washington, DC

⁹University of North Carolina at Chapel Hill, Chapel Hill, NC

Abstract

Purpose—Musculoskeletal events (MEs) resulting from breast cancer treatment can significantly interfere with the quality of life (QOL) of older adults. We evaluated the incidence of MEs in women 65 years and older who had surgery and adjuvant chemotherapy for breast cancer, and the impact of treatment on MEs and arm function.

Patients and Methods—Patient-reported data in Alliance/CALGB 49907 were collected using the EORTC QLQ-BR23 and physician-reported adverse events (AEs) to characterize self-reported MEs and incidence of lymphedema. EORTC QLQ-BR23 items related to musculoskeletal events were analyzed in this study and data collected at study entry (post-operative) and 12 and 24 months post entry.

Results—Lymphedema, arm function and ME data were available for 321 patients. One or more MEs were reported by 87% (median number=3) and 64% (median number=1) of patients post-operatively and at 24 months. At 24 months 2% had persistence of six MEs. Seventy-four percent experienced at least 3/6 types of MEs over the 24-month period. Detection of lymphedema at any time during the study was noted in 7.5% of the patients and appeared to be associated with type of

Correspondence: Judith O. Hopkins, MD, Novant Health Forsyth Medical Center 3333, Silas Creek Parkway, Winston-Salem, NC 27103, johopkins@novanthealth.org, Telephone: (336) 564-4170, Fax: (336) 564-4936.

The authors declare that they have no conflict of interest.

chemotherapy given: CMF 16.4%, capecitabine 5.8% and AC 4%. Mastectomy and axillary node dissection were associated with the most MEs. LROM correlated with poorer arm function at all time periods.

Conclusion—Potentially debilitating MEs occur in three-fourths of elderly women undergoing standard therapy for breast cancer. Emphasis should be placed on prevention, identification and treatment of these MEs to improve QOL.

Keywords

Breast Cancer; Elderly; Musculoskeletal Events; Lymphedema

Introduction

Musculoskeletal symptoms in older patients treated for potentially curable breast cancer occur frequently, but we have little data on self-reported symptoms and their effects on function and quality of life. This analysis seeks to address these gaps. Common signs and symptoms include lymphedema^[1, 2], self-reported arm or hand swelling^[3], breast pain^[4, 5], breast sensitivity^[5, 6], pain in the arm/shoulder^[3] and limitations in range of motion (LROM)^[3, 6]. The incidences of these symptoms vary and depend on the type of surgery^[1, 2, 7], receipt of radiation therapy^[1, 2], whether chemotherapy was administered, the type of chemotherapy^[7, 8, 9] and whether patients received aromatase inhibitors.

Lymphedema is of major concern with a meta-analysis of 72 studies showing a 17% risk of lymphedema after therapy^[10]. At least 20% of women who receive therapy for breast cancer experience arm/shoulder pain and 66% experience breast/chest wall pain^[5, 6]. A survey of patients of all ages at varying time intervals from original therapy revealed persistent operative site pain in 35% of 730 patients who underwent breast-conserving surgery (BCS) versus 30% who underwent mastectomy. Persistent arm swelling was self-reported in 14% who underwent BCS and 26% who underwent mastectomy, and LROM was reported in 32% having BCS versus 47% with mastectomy^[7].

In older women, musculoskeletal problems during and after treatment might have more profound effects on physical function and quality of life (QOL) than in younger women and such complications could impact an individual's ability to live independently. Cancer and Leukemia Group B (CALGB)/Alliance trial 49907 was a prospective randomized adjuvant trial of standard chemotherapy (doxorubicin and cyclophosphamide [AC] or cyclophosphamide, methotrexate, and fluorouracil [CMF]) versus capecitabine in women 65 and older with Stage I to III breast cancer^[11]. This study provides a unique opportunity for the prospective analysis of LE and self-reported musculoskeletal events and their effect on function and quality of life in this older population of breast cancer patients.

Methods

Alliance study 171302 is a secondary analysis of CALGB/Alliance 49907, the details of which have been previously published^[11]. Three hundred twenty-one of the CALGB 49907 patients were also enrolled in a QOL companion trial and as previously described were quite

similar in demographic and other characteristics to the overall group; professionally-assessed lymphedema and patient self-assessed QOL data form the basis of this analysis [12]. For this study we matched the lymphedema adverse event (AE) data with the 321 patients who provided QOL data. Each participant signed an IRB-approved, protocol-specific informed consent in accordance with federal and institutional guidelines.

Lymphedema AE data were graded per Common Toxicity Criteria version 2 [13] during follow-up visits with the physician and the maximum physician-reported lymphedema grade experienced by each patient was recorded. Grade 0 Lymphedema indicates no lymphedema. Grade 1 indicates mild lymphedema and grade 2 indicates moderate lymphedema requiring compression. Six patient-reported musculoskeletal events (MEs) from the EORTC QLQ-BR23 were utilized in this study: 1) pain in the arm/shoulder, 2) arm/hand swelling, 3) difficulty in raising arm or moving it sideways (limited range of motion, LROM), 4) breast pain in the affected breast, 5) breast swelling in the affected breast, and 6) oversensitivity in the affected breast. Patients reported on severity of these symptoms with the following descriptors: 1) not at all, 2) a little, 3) quite a bit, or 4) very much. Patients completed the assessments at three time points: study baseline (within 84 days following surgery), 12 months from baseline, and 24 months from baseline. Patients with mastectomy and BCS completed the same questionnaires; we considered breast pain, breast sensitivity and breast swelling as referring to chest wall symptoms in patients who underwent mastectomy. One of the questions asked of participants at all 3 time points was their ability to lift a shopping bag or suitcase. We felt this question was one assessment of arm function.

We performed an analysis of physician-reported lymphedema and patient-reported data to determine the incidence of lymphedema and the six MEs experienced (i.e., pain in arms/shoulder, arm/hand swelling, LROM, and pain, swelling, and sensitivity in the affected breast). The relationship of the most extensive surgery (BCS or mastectomy), axillary surgery, receipt of radiation, number of examined nodes, and chemotherapy type (AC, CMF, or capecitabine) to lymphedema and the six patient-reported MEs was also assessed. Data collection and statistical analyses were conducted by the Alliance Statistics and Data Center. Data quality was ensured by review of data by the Alliance Statistics and Data Center and by the study chairperson following Alliance policies. All analyses were based on the study database frozen on November 19, 2015. Patients were dichotomized for each of the seven endpoints described above, (lymphedema AE and the six MEs) in two ways: (1) any event: at least one grade 1 lymphedema event (vs. no lymphedema events) or an answer of “a little” or worse (vs. “none”) for each of the six MEs and (2) severe: at least one grade 3 lymphedema event (vs. <grade 3 lymphedema events) or an answer of “quite a bit” or “very much” (vs. “none” or “a little”) for each of the six MEs.

Patients who enrolled into Alliance/CALGB 49907 and who answered at least one of the six MEs listed above at baseline were included in these analyses (N=321). Although not all of the 321 patients provided answers for all six MEs being assessed (as noted in the figures and tables), all available data were analyzed for associations, which led to different sample sizes when comparing variables at a given time point.

Chi-squared tests [14] were used to determine if a given event happened at a higher or lower rate was associated with variables measured at baseline (most extensive surgery, axillary dissection, radiation, number of nodes examined, and chemotherapy type). These tests were performed at 3 time points: post-operative study entry and 12 and 24 months post study entry. Since any results will be viewed as hypothesis generating in general, all available data were used for each analysis and no adjustments were made for multiple comparisons.

Results

Of the 612 patients who participated in Alliance/CALGB 49907, both self-reported ME outcomes and physician-reported lymphedema (LE) data were available for 321 patients. These same patients also answered the question of whether or not they could lift a shopping bag or suitcase. The mean age was 72 years and 87% were Caucasian. Fifty-five percent underwent mastectomy and 45% BCS. Twenty percent had only a sentinel lymph node (SLN) biopsy and 80% had an axillary lymph node dissection (ALND). Fifty-four percent received radiation therapy (RT) and per protocol all received chemotherapy (48% capecitabine, 31% AC and 21% CMF) [Table 1].

Eight-seven percent had at least one self-reported ME at study baseline (within 84 days post-operative) and the median number of MEs at baseline was 3. By 12 months, 72% had persistence of at least one ME symptom and 64% had at least one lingering ME symptom at 24 months [Table 2].

Over this same 24-month period, 7.5% of these 321 women developed grade 1 or grade 2 LE [Table 3]. LE incidence was associated with type of chemotherapy received: CMF (13.4% grade 1 and 3.0% grade 2), capecitabine (4.5% grade 1 and 1.3% grade 2) and AC (4.0% grade 1 and 0% grade 2) [p=0.007]. There was no association between mastectomy or BCS and LE incidence (p=0.453) nor any association with receipt of RT or not (p=0.308) and lymphedema incidence. Performance of an ALND or not and removal of 8 ALNs was however associated with the development of LE (p=0.042 and p=0.023, respectively). If no ALND was performed, only 1.5% developed grade 1 LE but if an ALND was done, 7.4% developed grade 1 LE and 1.6% grade 2 (p=0.042). If 8 or more ALN were removed, 8.5% developed grade 1 LE and 1.9% grade 2 [Table 3].

Patient-reported arm/hand swelling at any time point post-surgery was significantly related to health care professional reported LE with p values from <0.001 to 0.003. Despite that association, only about 20% of women who reported arm/hand swelling over the 24-month period of the study developed sufficient LE to be noted by a healthcare professional. Conversely, 80% of women reporting arm/hand swelling were not noted to have enough swelling by healthcare professionals to diagnose LE [Table 4]. There was little change in arm/hand swelling over time from post-operative baseline, 12 months, and 24 months: 22%, 21%, and 20%, respectively [Figure 1]. Arm and hand swelling did not affect arm function (ability to lift a shopping bag or suitcase) at any of the measured periods (p=0.260, p=0.136, and p=0.060) [Table 5]. Presence of lymphedema did not affect arm function either (p=0.716) [Data not shown].

Limited range of motion as defined by difficulty in raising arm or moving it sideways did interfere with arm function at all measured time intervals: post-operative baseline $p < 0.001$; 12 months $p = 0.002$; and 24 months $p < 0.001$. Limited range of motion fell from 51% at baseline to 31% at 12 months and 21% by 24 months [Figure 1]. Breast sensitivity interfered with arm function in the post-operative ($p = 0.004$) and 12-month ($p = 0.038$) periods but resolved by 24 months ($p = 0.164$). Breast sensitivity was present in 59% of women post-operatively and declined to 40% at 12 months but persisted in 31% at 24 months [Figure 1]. Breast swelling also interfered with arm function at 12 months ($p = 0.018$) but surprisingly did not interfere in the post-operative or 24-month period: $p = 0.352$ and $p = 0.343$. Breast swelling was present in 46% of participants in the post-operative period and dropped to 12% by 12 months and 10% by 24 months [Figure 1]. Arm and shoulder pain significantly interfered with arm function at all three measured intervals: $p = 0.078$ post-operatively, $p = 0.005$ at 12 months, and $p = 0.001$ at 24 months. Arm and shoulder pain was seen in 63% at baseline, 49% at 12 months and 43% at 24 months [Figure 1]. Women with this post-operative arm/shoulder pain also experienced significant breast pain with an incidence of 57% at 12 months and 44% at 24 months ($p < 0.001$ and $p = 0.002$) respectively (Appendix Table 7). Breast pain only interfered with arm function in the post-operative period ($p < 0.001$). Similarly breast pain was also present at 59% at baseline, 47% at 12 months and 37% at 24 months.

Those that underwent an axillary dissection or had 8 axillary lymph nodes removed had an increased risk of arm/shoulder pain in the post-operative period with a 43% incidence ($p < 0.001$) and 71% incidence ($p < 0.001$) respectively. This association resolved by 12 months (Appendix Table 6).

Discussion

This study in older women with early stage breast cancer with prospectively collected data on professionally assessed lymphedema and self-reported musculoskeletal events is one of the few to address these complications in this age group, to evaluate these symptoms over time, and to correlate these symptom changes with function. The persistence of self-reported arm/hand swelling, limited range of motion and arm/shoulder pain at 24 months in a quarter or more of these older women is substantial and threatens their ability to live independently. LE is a major complication of surgery and radiation and our physician-reported LE incidence of 7.5% at any time over 24 months compared poorly to the incidence of patient-reported post-operative arm/hand swelling of 20% at 24 months. This discrepancy confirms current literature that shows that the incidence of treatment side-effects is higher when patient-reported compared to provider-reported, and may explain the large variability in the incidence of lymphedema that has been previously reported (0-56%) [15]. A recent review showed that patient-reported outcomes were indeed more accurate than provider adverse event reporting [16]. Part of the difference may be explained by our study's reliance on provider and not volumetric LE assessment, further underestimating true incidence.

Limited range of motion and arm/shoulder pain, as expected, interfered with arm function at all measured time intervals, while neither arm/hand swelling nor LE did. Our 63% incidence of arm/shoulder pain at baseline in older women is similar to another study that showed an

incidence of 60% in breast cancer survivors of all ages [17]. This latter study revealed a 67% incidence of decreased upper body strength while we found 60% of our patients had LROM and poor arm function (as defined by ability to lift a suitcase or shopping bag). Surprisingly, limited range of motion was not associated with lymphedema in our study [data not shown] in contradistinction to others [18]. For the elderly this may convert those living independently into those requiring assistance.

ALND and removal of 8 ALN as compared to breast-conserving surgery or mastectomy were associated with greater arm/hand swelling (see Appendix). Our findings regarding ALND versus not and removal of 8 ALN and their association with lymphedema, self-reported arm/hand swelling, limited range of motion, breast pain/sensitivity, and pain in arm/shoulder are similar to that seen in American College of Surgeons Oncology Group (Alliance) Z0011 [19] (ALND versus no ALND in women with invasive breast cancer and sentinel lymph node metastasis) and National Surgical Adjuvant Breast and Bowel Project (NSABP) B-32 [20, 21] (SLN versus ALND in clinically node negative breast cancer). For older women, our data and that of others suggest that the surgical approach of choice, if possible, is a lumpectomy and sentinel lymph node (SLN) biopsy [22].

Breast/chest wall swelling was commonly reported post-operatively but almost completely resolved by 24 months. It was more commonly reported in patients receiving radiation treatment, as was breast swelling and breast sensitivity, but this association was lost by 24 months. These findings may represent lymphedema of the breast and their resolution with time should be reassuring to clinicians and older women with these symptoms. The incidence of breast or chest wall pain in our elderly patients post-operatively, at 12 months, and at 24 months of 59%, 47% and 36%, respectively, was somewhat dissimilar to an analysis in breast cancer patients of all ages of 68% at 6 months⁶ and 66% at 12 months [23], and to another analysis that revealed persistent pain in 33% at 12 months [5]. Our data and that of others confirm that pain diminishes significantly over time. We also found that post-operative pain in the arm/shoulder was highly associated with continuing breast/chest wall pain and was increased with more extensive axillary surgery (data not shown). Limiting axillary surgery to sentinel lymph node biopsy or omitting it unless it will change treatment planning or outcomes, should help minimize these symptoms.

This study has several limitations. All patients were in good health and capable of participating in a clinical trial; therefore, these patients may differ from other older early stage breast cancer patients in the general population and our findings might underestimate the true frequency of musculoskeletal symptoms. Moreover, only one-half of the study population participated in the QOL portion of this study and not all ME data were available for each time point. We did not have baseline data on musculoskeletal events prior to surgery, nor what interventions or medications were implemented for these symptoms either before or after surgery and whether they affected the improvement in symptoms that were noted over time. Conversely, this is one of the few studies that prospectively captured these LE and ME complications in elderly patients on a clinical trial.

Overall, our data are reassuring and suggest that the frequency of major musculoskeletal symptoms in an older patient population participating in a clinical trial is substantial but

dramatically decreases with time. However, for many patients these symptoms are quite bothersome and affect quality of life. Oncologists should query older patients concerning musculoskeletal symptoms and refer patients for interventions when appropriate. In addition, these data should be shared with patients and families to optimize treatment planning.

Acknowledgments

Support: Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under the Award Number UG1CA189823 (Alliance for Clinical Trials in Oncology NCORP Grant), U10CA032291, U10CA047559, U10CA047577, U10CA077597, U10CA077651, U10CA180791, U10CA180838, U10CA180857, and U10CA180867. Supported, in part, by grants from the National Cancer Institute (U10CA031946 and U10CA033601), the National Institute on Aging (U10CA85850), the Breast Cancer Research Foundation, the Coalition of Cancer Cooperative Groups, and Roche Biomedical Laboratories. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Appendix

Table 1

Arm/Hand Swelling

		None	A little	Quite a bit	Very Much	p-value (little+)	p-value (quite a bit +)
POST OP	Overall ARM/HAND SWELLING (N=321)	250 (77.9%)	56 (17.4%)	11 (3.4%)	4 (1.2%)		
	Vs Arm (N=321)					0.572	0.720
	CMF (Cyclophosphamide, Methotrexate and Fluorouracil) (N=67)	49 (73.1%)	15 (22.4%)	2 (3.0%)	1 (1.5%)		
	AC (Doxorubicin and Cyclophosphamide) (N=99)	78 (78.8%)	15 (15.2%)	4 (4.0%)	2 (2.0%)		
	Capecitabine (N=155)	123 (79.4%)	26 (16.8%)	5 (3.2%)	1 (0.6%)		
	Vs Most Extensive Surgery (N=319)					0.621	0.359
	Breast Conserving Surgery (N=143)	113 (79.0%)	25 (17.5%)	4 (2.8%)	1 (0.7%)		
	Full Mastectomy (N=176)	135 (76.7%)	31 (17.6%)	7 (4.0%)	3 (1.7%)		
	Vs Axillary Dissection (N=321)					<0.001	0.046
	No (N=65)	62 (95.4%)	3 (4.6%)	0 (0%)	0 (0%)		
	Yes (N=256)	188 (73.4%)	53 (20.7%)	11 (4.3%)	4 (1.6%)		
	Vs RT (N=300)					0.570	0.789
	No (N=139)	110 (79.1%)	23 (16.6%)	4 (2.9%)	2 (1.4%)		
Yes (N=161)	123 (76.4%)	30 (18.6%)	6 (3.7%)	2 (1.2%)			
Vs Number of Nodes Examined (N=314)					<0.001	0.083	
0-3 (N=49)	45 (91.8%)	4 (8.2%)	0 (0%)	0 (0%)			

		None	A little	Quite a bit	Very Much	p-value (little+)	p-value (quite a bit +)
	4-7 (N=53)	49 (92.5%)	3 (5.7%)	1 (1.9%)	0 (0%)		
	8+ (N=212)	149 (70.3%)	49 (23.1%)	10 (4.7%)	4 (1.9%)		
AT 12 MONTHS	Overall ARM/HAND SWELLING (N=259)	205 (79.2%)	38 (14.7%)	12 (4.6%)	4 (1.5%)		
	Vs Arm (N=259)					0.957	0.226
	CMF (Cyclophosphamide, Methotrexate and Fluorouracil) (N=54)	43 (79.6%)	9 (16.7%)	2 (3.7%)	0 (0%)		
	AC (Doxorubicin and Cyclophosphamide) (N=82)	64 (78.1%)	10 (12.2%)	6 (7.3%)	2 (2.4%)		
	Capecitabine (N=123)	98 (79.7%)	19 (15.4%)	4 (3.3%)	2 (1.6%)		
	Vs Most Extensive Surgery (N=257)					0.968	0.929
	Breast Conserving Surgery (N=117)	93 (79.5%)	17 (14.5%)	5 (4.3%)	2 (1.7%)		
	Full Mastectomy (N=140)	111 (79.3%)	20 (14.3%)	7 (5.0%)	2 (1.4%)		
	Vs Axillary Dissection (N=259)					0.320	0.628
	No (N=56)	47 (83.9%)	5 (8.9%)	3 (5.4%)	1 (1.8%)		
Yes (N=203)	158 (77.8%)	33 (16.3%)	9 (4.4%)	3 (1.5%)			
Vs RT (N=245)					0.368	0.415	
No (N=109)	90 (82.6%)	14 (12.8%)	5 (4.6%)	0 (0%)			
Yes (N=136)	106 (77.9%)	21 (15.4%)	6 (4.4%)	3 (2.2%)			
Vs Number of Nodes Examined (N=254)					0.479	0.582	
0-3 (N=44)	37 (84.1%)	4 (9.1%)	3 (6.8%)	0 (0%)			
4-7 (N=39)	32 (82.1%)	3 (7.7%)	1 (2.6%)	3 (7.7%)			
8+ (N=171)	131 (76.6%)	31 (18.1%)	8 (4.7%)	1 (0.6%)			
AT 24 MONTHS	Overall ARM/HAND SWELLING (N=240)	193 (80.4%)	38 (15.8%)	8 (3.3%)	1 (0.4%)		
	Vs Arm (N=240)					0.116	0.211
	CMF (Cyclophosphamide, Methotrexate and Fluorouracil) (N=49)	36 (73.5%)	9 (18.4%)	3 (6.1%)	1 (2.0%)		
	AC (Doxorubicin and Cyclophosphamide) (N=83)	64 (77.1%)	17 (20.5%)	2 (2.4%)	0 (0%)		
	Capecitabine (N=108)	93 (86.1%)	12 (11.1%)	3 (2.8%)	0 (0%)		
Vs Most Extensive Surgery (N=238)					0.202	0.039	

		None	A little	Quite a bit	Very Much	p-value (little+)	p-value (quite a bit +)
	Breast Conserving Surgery (N=108)	91 (84.3%)	16 (14.8%)	1 (0.9%)	0 (0%)		
	Full Mastectomy (N=130)	101 (77.7%)	21 (16.2%)	7 (5.3%)	1 (0.8%)		
	Vs Axillary Dissection (N=240)					0.209	0.489
	No (N=52)	45 (86.5%)	6 (11.5%)	1 (1.9%)	0 (0%)		
	Yes (N=188)	148 (77.7%)	32 (17.0%)	7 (3.7%)	1 (0.5%)		
	Vs RT (N=226)					0.522	0.833
	No (N=100)	82 (82.0%)	14 (14.0%)	4 (4.0%)	0 (0%)		
	Yes (N=126)	99 (78.6%)	23 (18.3%)	3 (2.4%)	1 (0.8%)		
	Vs Number of Nodes Examined (N=236)					0.079	0.406
	0-3 (N=41)	38 (92.7%)	2 (4.9%)	1 (2.4%)	0 (0%)		
	4-7 (N=39)	31 (79.5%)	5 (12.8%)	2 (5.1%)	1 (2.6%)		
	8+ (N=156)	120 (76.9%)	31 (19.9%)	5 (3.2%)	0 (0%)		

Table 2**Limited Range of Motion**

		None	A little	Quite a bit	Very Much	p-value (little+)	p-value (quite a bit +)
	Overall LROM (N=320)	157 (49.1%)	125 (39.1%)	31 (9.7%)	7 (2.2%)		
	Vs Arm (N=320)					0.929	0.698
	CMF (Cyclophosphamide, Methotrexate and Fluorouracil) (N=67)	33 (49.3%)	28 (41.8%)	5 (7.5%)	1 (1.5%)		
	AC (Doxorubicin and Cyclophosphamide) (N=99)	50 (50.5%)	36 (36.4%)	11 (11.1%)	2 (2.0%)		
	Capecitabine (N=154)	74 (48.1%)	61 (39.6%)	15 (9.7%)	4 (2.6%)		
	Vs Most Extensive Surgery (N=318)					0.034	0.480
	Breast Conserving Surgery (N=143)	80 (55.9%)	48 (33.6%)	14 (9.8%)	1 (0.7%)		
	Full Mastectomy (N=175)	77 (44.0%)	75 (42.9%)	17 (9.7%)	6 (3.4%)		
	Vs Axillary Dissection (N=320)					<0.001	0.466
	No (N=65)	48 (73.8%)	11 (16.9%)	6 (9.2%)	0 (0%)		
	Yes (N=255)	109 (42.7%)	114 (44.7%)	25 (9.8%)	7 (2.7%)		

		None	A little	Quite a bit	Very Much	p-value (little+)	p-value (quite a bit +)
	Vs RT (N=299)					0.668	0.938
	No (N=138)	66 (47.8%)	56 (40.6%)	14 (10.1%)	2 (1.4%)		
	Yes (N=161)	81 (50.3%)	61 (37.9%)	16 (9.9%)	3 (1.9%)		
	Vs Number of Nodes Examined (N=313)					<0.001	0.871
	0-3 (N=49)	35 (71.4%)	9 (18.4%)	5 (10.2%)	0 (0%)		
	4-7 (N=53)	32 (60.4%)	15 (28.3%)	6 (11.3%)	0 (0%)		
8+ (N=211)	85 (40.3%)	99 (46.9%)	20 (9.5%)	7 (3.3%)			
AT 12 MONTHS	Overall LROM (N=259)	179 (69.1%)	63 (24.3%)	14 (5.4%)	3 (1.2%)		
	Vs Arm (N=259)					0.779	0.666
	CMF (Cyclophosphamide, Methotrexate and Fluorouracil) (N=54)	36 (66.7%)	15 (27.8%)	2 (3.7%)	1 (1.9%)		
	AC (Doxorubicin and Cyclophosphamide) (N=82)	59 (72.0%)	19 (23.2%)	4 (4.9%)	0 (0%)		
	Capecitabine (N=123)	84 (68.3%)	29 (23.6%)	8 (6.5%)	2 (1.6%)		
	Vs Most Extensive Surgery (N=257)					0.339	0.417
	Breast Conserving Surgery (N=117)	85 (72.6%)	26 (22.2%)	5 (4.3%)	1 (0.9%)		
	Full Mastectomy (N=140)	94 (67.1%)	35 (25.0%)	9 (6.4%)	2 (1.4%)		
	Vs Axillary Dissection (N=259)					0.160	0.730
	No (N=56)	43 (76.8%)	9 (16.1%)	4 (7.1%)	0 (0%)		
	Yes (N=203)	136 (67.0%)	54 (26.6%)	10 (4.9%)	3 (1.4%)		
	Vs RT (N=245)					0.796	0.467
No (N=109)	77 (70.6%)	26 (23.9%)	5 (4.6%)	1 (0.9%)			
Yes (N=136)	94 (69.1%)	32 (23.5%)	8 (5.9%)	2 (1.5%)			
Vs Number of Nodes Examined (N=254)					0.536	0.904	
0-3 (N=44)	33 (75.0%)	9 (20.5%)	2 (4.5%)	0 (0%)			
4-7 (N=39)	25 (64.1%)	11 (28.2%)	3 (7.7%)	0 (0%)			
8+ (N=171)	116 (67.8%)	43 (25.1%)	9 (5.3%)	3 (1.8%)			
AT 24 MONTHS	Overall LROM (N=240)	190 (79.1%)	39 (16.3%)	8 (3.3%)	3 (1.3%)		
	Vs Arm (N=240)					0.096	0.120
	CMF (Cyclophosphamide, Methotrexate and Fluorouracil) (N=49)	35 (71.4%)	10 (20.4%)	3 (6.1%)	1 (2.0%)		

		None	A little	Quite a bit	Very Much	p-value (little+)	p-value (quite a bit +)
	AC (Doxorubicin and Cyclophosphamide) (N=83)	63 (75.9%)	15 (18.1%)	4 (4.8%)	1 (1.2%)		
	Capecitabine (N=108)	92 (85.2%)	14 (13.0%)	1 (0.9%)	1 (0.9%)		
	Vs Most Extensive Surgery (N=238)					0.028	0.234
	Breast Conserving Surgery (N=108)	93 (86.1%)	12 (11.1%)	3 (2.8%)	0 (0%)		
	Full Mastectomy (N=130)	97 (74.6%)	25 (19.2%)	5 (3.8%)	3 (2.3%)		
	Vs Axillary Dissection (N=240)					0.748	0.862
	No (N=52)	42 (80.8%)	8 (15.4%)	2 (3.8%)	0 (0%)		
	Yes (N=188)	148 (78.7%)	31 (16.5%)	6 (3.2%)	3 (1.6%)		
	Vs RT (N=226)					0.691	0.292
	No (N=100)	78 (78.0%)	19 (19.0%)	3 (3.0%)	0 (0%)		
	Yes (N=126)	101 (80.2%)	18 (14.3%)	5 (4.0%)	2 (1.6%)		
	Vs Number of Nodes Examined (N=236)					0.465	0.832
	0-3 (N=41)	34 (82.9%)	6 (14.6%)	1 (2.4%)	0 (0%)		
	4-7 (N=39)	33 (84.6%)	4 (10.3%)	0 (0%)	2 (5.1%)		
	8+ (N=156)	120 (76.9%)	28 (18.0%)	7 (4.5%)	1 (0.6%)		

Table 3**Breast Swelling**

		None	A little	Quite a bit	Very Much	p-value (little+)	p-value (quite a bit +)
	Overall Breast Swelling (N=320)	172 (53.8%)	121 (37.8%)	19 (5.9%)	8 (2.5%)		
	Vs Arm (N=320)					0.324	0.476
	CMF (Cyclophosphamide, Methotrexate and Fluorouracil) (N=66)	33 (50.0%)	29 (43.9%)	2 (3.0%)	2 (3.0%)		
	AC (Doxorubicin and Cyclophosphamide) (N=99)	49 (49.5%)	43 (43.4%)	4 (4.0%)	3 (3.0%)		
	Capecitabine (N=155)	90 (58.1%)	49 (31.6%)	13 (8.4%)	3 (1.9%)		
	Vs Most Extensive Surgery (N=318)					0.981	0.395
	Breast Conserving Surgery (N=143)	77 (53.8%)	56 (39.2%)	6 (4.2%)	4 (2.8%)		

		None	A little	Quite a bit	Very Much	p-value (little+)	p-value (quite a bit +)
	Full Mastectomy (N=175)	94 (53.7%)	64 (36.6%)	13 (7.4%)	4 (2.3%)		
	Vs Axillary Dissection (N=320)					0.091	0.463
	No (N=65)	41 (63.1%)	20 (30.8%)	2 (3.1%)	2 (3.1%)		
	Yes (N=255)	131 (51.4%)	101 (39.6%)	17 (6.7%)	6 (2.4%)		
	Vs RT (N=300)					0.029	0.507
	No (N=139)	84 (60.4%)	45 (32.4%)	9 (6.5%)	1 (0.7%)		
	Yes (N=161)	77 (47.8%)	69 (42.9%)	9 (5.6%)	6 (3.7%)		
	Vs Number of Nodes Examined (N=313)					0.065	0.562
	0-3 (N=49)	33 (67.3%)	13 (26.5%)	1 (2.0%)	2 (4.1%)		
	4-7 (N=53)	31 (58.5%)	19 (35.8%)	1 (1.9%)	2 (3.8%)		
	8+ (N=211)	105 (49.8%)	86 (40.8%)	16 (7.6%)	4 (1.9%)		
	Overall Breast Swelling (N=257)	225 (87.5%)	25 (9.7%)	5 (1.9%)	2 (0.8%)		
	Vs Arm (N=257)					0.764	0.452
	CMF (Cyclophosphamide, Methotrexate and Fluorouracil) (N=54)	48 (88.9%)	5 (9.3%)	0 (0%)	1 (1.9%)		
	AC (Doxorubicin and Cyclophosphamide) (N=82)	73 (89.0%)	8 (9.8%)	1 (1.2%)	0 (0%)		
	Capecitabine (N=121)	104 (86.0%)	12 (9.9%)	4 (3.3%)	1 (0.8%)		
	Vs Most Extensive Surgery (N=255)					0.329	0.028
	Breast Conserving Surgery (N=115)	98 (85.21%)	11 (9.6%)	5 (4.3%)	1 (0.9%)		
	Full Mastectomy (N=140)	125 (89.3%)	14 (10.0%)	0 (0%)	1 (0.7%)		
	Vs Axillary Dissection (N=257)					0.076	0.691
	No (N=55)	52 (94.5%)	2 (3.6%)	1 (1.8%)	0 (0%)		
	Yes (N=202)	173 (85.6%)	23 (11.4%)	4 (2.0%)	2 (1.0%)		
	Vs RT (N=243)					0.011	0.013
	No (N=109)	102 (93.6%)	7 (6.4%)	0 (0%)	0 (0%)		
	Yes (N=134)	111 (82.8%)	16 (11.9%)	5 (3.7%)	2 (1.5%)		
	Vs Number of Nodes Examined (N=252)					0.097	0.172
	0-3 (N=43)	41 (95.3%)	1 (2.3%)	1 (2.3%)	0 (0%)		
	4-7 (N=39)	31 (79.5%)	5 (12.8%)	1 (2.6%)	2 (5.1%)		
	8+ (N=170)	148 (87.1%)	19 (11.2%)	3 (1.8%)	0 (0%)		
AT 12 MONTHS							

		None	A little	Quite a bit	Very Much	p-value (little+)	p-value (quite a bit +)
AT 24 MONTHS	Overall Breast Swelling (N=240)	217 (90.4%)	21 (8.8%)	1 (0.4%)	1 (0.4%)		
	Vs Arm (N=240)					0.742	0.363
	CMF (Cyclophosphamide, Methotrexate and Fluorouracil) (N=49)	43 (87.8%)	5 (10.2%)	0 (0%)	1 (2.0%)		
	AC (Doxorubicin and Cyclophosphamide) (N=83)	75 (90.4%)	7 (8.4%)	1 (1.2%)	0 (0%)		
	Capecitabine (N=108)	99 (91.7%)	9 (8.3%)	0 (0%)	0 (0%)		
	Vs Most Extensive Surgery (N=238)					0.804	0.201
	Breast Conserving Surgery (N=108)	97 (89.8%)	11 (10.2%)	0 (0%)	0 (0%)		
	Full Mastectomy (N=130)	118 (90.8%)	10 (7.7%)	1 (0.8%)	1 (0.8%)		
	Vs Axillary Dissection (N=240)					0.112	0.475
	No (N=52)	50 (96.2%)	2 (3.8%)	0 (0%)	0 (0%)		
	Yes (N=188)	167 (88.8%)	19 (10.1%)	1 (0.5%)	1 (0.5%)		
	Vs RT (N=226)					0.551	0.919
	No (N=100)	92 (92.0%)	7 (7.0%)	1 (1.0%)	0 (0%)		
Yes (N=126)	113 (89.7%)	12 (9.5%)	0 (0%)	1 (0.8%)			
Vs Number of Nodes Examined (N=236)					0.509	0.425	
0-3 (N=41)	39 (95.1%)	2 (4.9%)	0 (0%)	0 (0%)			
4-7 (N=39)	35 (89.7%)	3 (7.7%)	0 (0%)	1 (2.6%)			
8+ (N=156)	139 (89.1%)	16 (10.3%)	1 (0.6%)	0 (0%)			

Table 4

Breast Sensitivity

		None	A little	Quite a bit	Very Much	p-value (little+)	p-value (quite a bit +)
POST OP	Overall Breast Sensitivity (N=320)	132 (41.3%)	146 (45.6%)	33 (10.3%)	9 (2.8%)		
	Vs Arm (N=320)					0.126	0.447
	CMF (Cyclophosphamide, Methotrexate and Fluorouracil) (N=66)	20 (30.3%)	38 (57.6%)	6 (9.1%)	2 (3.0%)		

		None	A little	Quite a bit	Very Much	p-value (little+)	p-value (quite a bit +)
	AC (Doxorubicin and Cyclophosphamide) (N=99)	43 (43.4%)	46 (46.5%)	9 (9.1%)	1 (1.0%)		
	Capecitabine (N=155)	69 (44.5%)	62 (40.0%)	18 (11.6%)	6 (3.9%)		
	Vs Most Extensive Surgery (N=318)					0.176	0.530
	Breast Conserving Surgery (N=143)	53 (37.1%)	73 (51.0%)	14 (9.8%)	3 (2.1%)		
	Full Mastectomy (N=175)	78 (44.6%)	72 (41.1%)	19 (10.9%)	6 (3.4%)		
	Vs Axillary Dissection (N=320)					0.081	0.062
	No (N=65)	33 (50.8%)	28 (43.1%)	3 (4.6%)	1 (1.5%)		
	Yes (N=255)	99 (38.8%)	118 (46.3%)	30 (11.8%)	8 (3.1%)		
	Vs RT (N=300)					0.019	0.051
	No (N=139)	67 (48.2%)	60 (43.2%)	9 (6.5%)	3 (2.2%)		
	Yes (N=161)	56 (34.8%)	79 (49.1%)	22 (13.7%)	4 (2.5%)		
	Vs Number of Nodes Examined (N=313)					0.137	0.424
	0-3 (N=49)	23 (46.9%)	21 (42.9%)	4 (8.2%)	1 (2.0%)		
	4-7 (N=53)	27 (50.9%)	21 (39.6%)	3 (5.7%)	2 (3.8%)		
	8+ (N=211)	79 (37.4%)	100 (47.4%)	26 (12.3%)	6 (2.8%)		
AT 12 MONTHS	Overall Breast Sensitivity (N=258)	154 (59.7%)	90 (34.9%)	11 (4.3%)	3 (1.2%)		
	Vs Arm (N=258)					0.014	0.343
	CMF (Cyclophosphamide, Methotrexate and Fluorouracil) (N=54)	24 (44.4%)	26 (48.2%)	2 (3.7%)	2 (3.7%)		
	AC (Doxorubicin and Cyclophosphamide) (N=82)	57 (69.5%)	23 (28.1%)	2 (2.4%)	0 (0%)		
	Capecitabine (N=122)	73 (59.8%)	41 (33.6%)	7 (5.7%)	1 (0.8%)		
	Vs Most Extensive Surgery (N=256)					<0.001	0.440
	Breast Conserving Surgery (N=117)	57 (48.7%)	55 (47.0%)	4 (3.4%)	1 (0.9%)		
	Full Mastectomy (N=139)	96 (69.1%)	34 (24.5%)	7 (5.0%)	2 (1.4%)		
	Vs Axillary Dissection (N=258)					0.043	0.043
	No (N=56)	40 (71.4%)	16 (28.6%)	0 (0%)	0 (0%)		
Yes (N=202)	114 (56.4%)	74 (36.6%)	11 (5.4%)	3 (1.5%)			
Vs RT (N=244)					<0.001	0.643	
No (N=109)	84 (77.1%)	20 (18.3%)	5 (4.6%)	0 (0%)			

		None	A little	Quite a bit	Very Much	p-value (little+)	p-value (quite a bit +)
	Yes (N=135)	61 (45.2%)	66 (48.9%)	5 (3.7%)	3 (2.2%)		
	Vs Number of Nodes Examined (N=253)					0.725	0.201
	0-3 (N=44)	27 (61.4%)	17 (38.6%)	0 (0%)	0 (0%)		
	4-7 (N=39)	25 (64.1%)	11 (28.2%)	1 (2.6%)	2 (5.1%)		
	8+ (N=170)	98 (57.6%)	61 (35.9%)	10 (5.9%)	1 (0.6%)		
AT 24 MONTHS	Overall Breast Sensitivity (N=239)	166 (69.5%)	62 (25.9%)	8 (3.3%)	3 (1.3%)		
	Vs Arm (N=239)					0.140	0.724
	CMF (Cyclophosphamide, Methotrexate and Fluorouracil) (N=49)	32 (65.3%)	15 (30.6%)	1 (2.0%)	1 (2.0%)		
	AC (Doxorubicin and Cyclophosphamide) (N=82)	52 (63.4%)	25 (30.5%)	3 (3.7%)	2 (2.4%)		
	Capecitabine (N=108)	82 (75.9%)	22 (20.4%)	4 (3.7%)	0 (0%)		
	Vs Most Extensive Surgery (N=237)					0.320	0.103
	Breast Conserving Surgery (N=107)	78 (72.9%)	27 (25.2%)	2 (1.9%)	0 (0%)		
	Full Mastectomy (N=130)	87 (66.9%)	35 (26.9%)	5 (3.8%)	3 (2.3%)		
	Vs Axillary Dissection (N=239)					0.003	0.077
	No (N=51)	44 (86.3%)	7 (13.7%)	0 (0%)	0 (0%)		
	Yes (N=188)	122 (64.9%)	55 (29.3%)	8 (4.3%)	3 (1.6%)		
	Vs RT (N=225)					0.347	0.494
	No (N=100)	73 (73.0%)	24 (24.0%)	3 (3.0%)	0 (0%)		
Yes (N=125)	84 (67.2%)	365(28.0%)	3 (2.4%)	3 (2.4%)			
Vs Number of Nodes Examined (N=235)					0.293	0.756	
0-3 (N=41)	29 (70.7%)	11 (26.8%)	1 (2.4%)	0 (0%)			
4-7 (N=38)	30 (79.0%)	6 (15.8%)	1 (2.6%)	1 (2.6%)			
8+ (N=156)	103 (66.0%)	45 (28.9%)	6 (3.8%)	2 (1.3%)			

Table 5

Breast Pain

		None	A little	Quite a bit	Very Much	p-value (little+)	p-value (quite a bit +)
POST OP	Overall Breast Pain (N=318)	130 (40.9%)	165 (51.9%)	21 (6.6%)	2 (0.6%)		
	Vs Arm (N=318)					0.364	0.863
	CMF (Cyclophosphamide, Methotrexate and Fluorouracil) (N=65)	22 (33.8%)	38 (58.5%)	4 (6.2%)	1 (1.5%)		
	AC (Doxorubicin and Cyclophosphamide) (N=99)	40 (40.4%)	53 (53.5%)	5 (5.1%)	1 (1.0%)		
	Capecitabine (N=154)	68 (44.2%)	74 (48.1%)	12 (7.8%)	0 (0%)		
	Vs Most Extensive Surgery (N=316)					0.031	0.540
	Breast Conserving Surgery (N=143)	49 (34.3%)	85 (59.4%)	9 (6.3%)	0 (0%)		
	Full Mastectomy (N=173)	80 (46.2%)	79 (45.7%)	12 (6.9%)	2 (1.2%)		
	Vs Axillary Dissection (N=318)					0.210	0.147
	No (N=65)	31 (47.7%)	32 (49.2%)	2 (3.1%)	0 (0%)		
	Yes (N=253)	99 (39.1%)	133 (52.6%)	19 (7.5%)	2 (0.8%)		
	AT 12 MONTHS	Vs RT (N=298)					0.007
No (N=137)		68 (49.6%)	62 (45.3%)	6 (4.4%)	1 (0.7%)		
Yes (N=161)		55 (34.2%)	93 (57.8%)	12 (7.5%)	1 (0.6%)		
Vs Number of Nodes Examined (N=311)						0.846	0.038
0-3 (N=49)		21 (42.9%)	27 (55.1%)	1 (2.0%)	0 (0%)		
4-7 (N=53)		23 (43.4%)	29 (54.7%)	0 (0%)	1 (1.9%)		
8+ (N=209)		83 (39.7%)	105 (50.2%)	20 (9.6%)	1 (0.5%)		
Overall Breast Pain (N=259)		137 (52.9%)	109 (42.1%)	8 (3.1%)	5 (1.9%)		
Vs Arm (N=259)						0.061	0.157
CMF (Cyclophosphamide, Methotrexate and Fluorouracil) (N=54)		21 (38.9%)	29 (53.7%)	2 (3.7%)	2 (3.7%)		
AC (Doxorubicin and Cyclophosphamide) (N=82)	48 (58.5%)	33 (40.2%)	0 (0%)	1 (1.2%)			
Capecitabine (N=123)	68 (55.3%)	47 (38.2%)	6 (4.9%)	2 (1.6%)			
Vs Most Extensive Surgery (N=257)					0.006	0.234	

		None	A little	Quite a bit	Very Much	p-value (little+)	p-value (quite a bit +)
	Breast Conserving Surgery (N=117)	51 (43.6%)	58 (49.6%)	6 (5.1%)	2 (1.7%)		
	Full Mastectomy (N=140)	85 (60.7%)	50 (35.7%)	2 (1.4%)	3 (2.1%)		
	Vs Axillary Dissection (N=259)					0.909	0.896
	No (N=56)	30 (53.6%)	23 (41.1%)	1 (1.8%)	2 (3.6%)		
	Yes (N=203)	107 (52.7%)	86 (42.4%)	7 (3.4%)	3 (1.5%)		
	Vs RT (N=245)					<0.001	0.006
	No (N=109)	74 (67.9%)	34 (31.8%)	1 (0.9%)	0 (0%)		
	Yes (N=136)	55 (40.4%)	69 (50.7%)	7 (5.1%)	5 (3.7%)		
	Vs Number of Nodes Examined (N=254)					0.708	0.284
	0-3 (N=44)	22 (50.0%)	20 (45.5%)	1 (2.3%)	1 (2.2%)		
	4-7 (N=39)	23 (59.0%)	12 (30.8%)	1 (2.6%)	3 (7.7%)		
	8+ (N=171)	91 (53.2%)	73 (42.7%)	6 (3.5%)	1 (0.6%)		
AT 24 MONTHS	Overall Breast Pain (N=240)	152 (63.3%)	78 (32.5%)	8 (3.3%)	2 (0.8%)		
	Vs Arm (N=240)					0.214	0.744
	CMF (Cyclophosphamide, Methotrexate and Fluorouracil) (N=49)	26 (53.1%)	20 (40.8%)	2 (4.1%)	1 (2.0%)		
	AC (Doxorubicin and Cyclophosphamide) (N=83)	53 (63.9%)	27 (32.5%)	2 (2.4%)	1 (1.2%)		
	Capecitabine (N=108)	73 (67.6%)	31 (28.7%)	4 (3.7%)	0 (0%)		
	Vs Most Extensive Surgery (N=238)					0.281	0.100
	Breast Conserving Surgery (N=108)	65 (60.2%)	41 (38.0%)	2 (1.9%)	0 (0%)		
	Full Mastectomy (N=130)	87 (66.9%)	35 (26.9%)	6 (4.6%)	2 (1.5%)		
	Vs Axillary Dissection (N=240)					0.049	0.089
	No (N=52)	39 (75.0%)	13 (25.0%)	0 (0%)	0 (0%)		
Yes (N=188)	113 (60.1%)	65 (34.6%)	8 (4.3%)	2 (1.1%)			
Vs RT (N=226)					0.032	0.990	
No (N=100)	71 (71.0%)	25 (25.0%)	4 (4.0%)	0 (0%)			
Yes (N=126)	72 (57.1%)	49 (38.9%)	3 (2.4%)	2 (1.6%)			
Vs Number of Nodes Examined (N=236)					0.265	0.334	
0-3 (N=41)	24 (58.5%)	17 (41.5%)	0 (0%)	0 (0%)			
4-7 (N=39)	29 (74.4%)	8 (20.5%)	1 (2.6%)	1 (2.6%)			

		None	A little	Quite a bit	Very Much	p-value (little+)	p-value (quite a bit +)
	8+ (N=156)	96 (61.5%)	52 (33.3%)	7 (4.5%)	1 (0.6%)		

Table 6

Arm/Shoulder Pain

		None	A little	Quite a bit	Very Much	p-value (little+)	p-value (quite a bit +)
POST OP	Overall Arm/Shoulder Pain (N=321)	118 (36.8%)	148 (46.1%)	45 (14.0%)	10 (3.1%)		
	Vs Arm (N=321)					0.218	0.656
	CMF (Cyclophosphamide, Methotrexate and Fluorouracil) (N=67)	19 (28.4%)	34 (50.8%)	14 (20.9%)	0 (0%)		
	AC (Doxorubicin and Cyclophosphamide) (N=99)	36 (36.4%)	47 (47.5%)	14 (14.1%)	2 (2.0%)		
	Capecitabine (N=155)	63 (40.6%)	67 (43.2%)	17 (11.0%)	8 (5.2%)		
	Vs Most Extensive Surgery (N=319)					0.834	0.276
	Breast Conserving Surgery (N=143)	52 (36.4%)	70 (49.0%)	17 (11.9%)	4 (2.8%)		
	Full Mastectomy (N=176)	66 (37.5%)	76 (43.2%)	28 (15.9%)	6 (3.4%)		
	Vs Axillary Dissection (N=321)					<0.001	0.009
	No (N=65)	37 (56.9%)	24 (36.9%)	4 (6.2%)	0 (0%)		
Yes (N=256)	81 (31.6%)	124 (48.4%)	41 (16.0%)	10 (3.9%)			
Vs RT (N=300)					0.112	0.397	
No (N=139)	59 (42.4%)	60 (43.2%)	15 (10.8%)	5 (3.6%)			
Yes (N=161)	54 (33.5%)	78 (48.4%)	25 (15.5%)	4 (2.5%)			
Vs Number of Nodes Examined (N=314)					<0.001	0.087	
0-3 (N=49)	25 (51.0%)	18 (36.7%)	6 (12.2%)	0 (0%)			
4-7 (N=53)	28 (52.8%)	20 (37.7%)	5 (9.4%)	0 (0%)			
8+ (N=212)	62 (29.2%)	106 (50.0%)	34 (16.0%)	10 (4.7%)			
AT 12 MONTHS	Overall Arm/Shoulder Pain (N=259)	133 (51.4%)	96 (37.1%)	22 (8.5%)	8 (3.1%)		
	Vs Arm (N=259)					0.514	0.274
	CMF (Cyclophosphamide,	24 (44.4%)	24 (44.4%)	5 (9.3%)	1 (1.9%)		

		None	A little	Quite a bit	Very Much	p-value (little+)	p-value (quite a bit +)
	Methotrexate and Fluorouracil (N=54)						
	AC (Doxorubicin and Cyclophosphamide) (N=82)	43 (52.4%)	33 (40.2%)	5 (6.1%)	1 (1.2%)		
	Capecitabine (N=123)	66 (53.7%)	39 (31.7%)	12 (9.8%)	6 (4.9%)		
	Vs Most Extensive Surgery (N=257)					0.523	0.798
	Breast Conserving Surgery (N=117)	58 (49.6%)	46 (39.3%)	9 (7.7%)	4 (3.4%)		
	Full Mastectomy (N=140)	75 (53.6%)	48 (34.3%)	13 (9.3%)	4 (2.9%)		
	Vs Axillary Dissection (N=259)					0.327	0.475
	No (N=56)	32 (57.1%)	16 (28.6%)	6 (10.7%)	2 (3.6%)		
	Yes (N=203)	101 (49.8%)	80 (39.4%)	16 (7.9%)	6 (3.0%)		
	Vs RT (N=245)					0.074	0.556
	No (N=109)	63 (57.8%)	35 (32.1%)	9 (8.3%)	2 (1.8%)		
	Yes (N=136)	63 (46.3%)	56 (41.2%)	11 (8.1%)	6 (4.4%)		
	Vs Number of Nodes Examined (N=254)					0.741	0.878
	0-3 (N=44)	25 (56.8%)	13 (29.5%)	4 (9.1%)	2 (4.5%)		
	4-7 (N=39)	20 (51.3%)	14 (35.9%)	5 (12.8%)	0 (0%)		
	8+ (N=171)	86 (50.3%)	66 (38.6%)	13 (7.6%)	6 (3.5%)		
	Overall Arm/Shoulder Pain (N=240)	136 (56.7%)	83 (34.6%)	16 (6.7%)	5 (2.1%)		
	Vs Arm (N=240)					0.069	0.104
	CMF (Cyclophosphamide, Methotrexate and Fluorouracil) (N=49)	24 (50.0%)	20 (40.8%)	3 (6.1%)	2 (4.1%)		
	AC (Doxorubicin and Cyclophosphamide) (N=83)	42 (50.6%)	30 (36.1%)	9 (10.8%)	2 (2.4%)		
	Capecitabine (N=108)	70 (64.8%)	33 (30.6%)	4 (3.7%)	1 (0.9%)		
AT 24 MONTHS	Vs Most Extensive Surgery (N=238)					0.851	0.149
	Breast Conserving Surgery (N=108)	61 (56.5%)	41 (38.0%)	5 (4.6%)	1 (0.9%)		
	Full Mastectomy (N=130)	75 (57.7%)	41 (31.5%)	10 (7.7%)	4 (3.1%)		
	Vs Axillary Dissection (N=240)					0.883	0.049
	No (N=52)	29 (55.8%)	22 (42.3%)	1 (1.9%)	0 (0%)		
	Yes (N=188)	107 (56.9%)	61 (32.4%)	15 (8.0%)	5 (2.7%)		
	Vs RT (N=226)					0.346	0.453

	None	A little	Quite a bit	Very Much	p-value (little+)	p-value (quite a bit +)
No (N=100)	61 (61.0%)	30 (30.0%)	9 (9.0%)	0 (0%)		
Yes (N=126)	69 (54.8%)	49 (38.9%)	4 (3.2%)	4 (3.2%)		
Vs Number of Nodes Examined (N=236)					0.788	0.229
0-3 (N=41)	25 (61.0%)	15 (36.6%)	1 (2.4%)	0 (0%)		
4-7 (N=39)	21 (53.9%)	15 (38.5%)	2 (5.1%)	1 (2.6%)		
8+ (N=156)	87 (55.8%)	52 (33.3%)	13 (8.3%)	4 (2.6%)		

Table 7

Post Op Arm/Shoulder Pain versus Breast Pain

	Breast Pain – 12 months post op	p-value
Arm/Shoulder Pain at Post Op (N=259)		<0.001
Yes (N=161)	91 (56.5%)	
No (N=98)	31 (31.6%)	
	Breast Pain – 24 months post op	
Arm/Shoulder Pain at Post Op (N=240)		0.002
Yes (N=149)	66 (44.3%)	
No (N=91)	22 (24.2%)	

References

- Shah C, Arthur D, Riutta J, et al. Breast-cancer related lymphedema: a review of procedure-specific incidence rates, clinical assessment AIDS, treatment paradigms, and risk reduction. *Breast J.* 2012; 18:357–61. [PubMed: 22759095]
- Ozcinar B, Guler SA, Kocaman N, et al. Breast cancer related lymphedema in patients with different loco-regional treatments. *Breast.* 2012; 21:361–5. [PubMed: 22460058]
- Kwan W, Jackson J, Weir LM, et al. Chronic arm morbidity after curative breast cancer treatment: prevalence and impact on quality of life. *J Clin Oncol.* 2002; 20:4242–8. [PubMed: 12377968]
- Tasmuth T, von Smitten K, Kalso E. Pain and other symptoms during the first year after radical and conservative surgery for breast cancer. *Br J Cancer.* 1996; 74:2024–31. [PubMed: 8980408]
- Miaskowski C, Cooper B, Paul SM, et al. Identification of patient subgroups and risk factors for persistent breast pain following breast cancer surgery. *J Pain.* 2012; 13:1172–87. [PubMed: 23182226]
- Karki A, Simonen R, Malkia E, et al. Impairments, activity limitations and participation restrictions 6 and 12 months after breast cancer operation. *J Rehabil Med.* 2005; 37:180–8. [PubMed: 16040476]
- Feiten S, Dunnebacke J, Heymanns J, et al. Breast cancer morbidity: questionnaire survey of patients on the long term effects of disease and adjuvant therapy. *Dtsch Arztebl Int.* 2014; 111:537–44. [PubMed: 25145512]
- Norman SA, Localio AR, Kallan MJ, et al. Risk factors for lymphedema after breast cancer treatment. *Cancer Epidemiol Biomarkers Prev.* 2010; 19:2734–46. [PubMed: 20978176]

9. Crew KD, Greenlee H, Capodice J, et al. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. *J Clin Oncol.* 2007; 25:3877–83. [PubMed: 17761973]
10. DiSipio T, Rye S, Newman B, et al. Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis. *Lancet Oncol.* 2013; 14:500–15. [PubMed: 23540561]
11. Muss HB, Berry DA, Cirincione CT, et al. Adjuvant chemotherapy in older women with early-stage breast cancer. *N Engl J Med.* 2009; 360:2055–65. [PubMed: 19439741]
12. Kornblith AB, Lan L, Archer L, et al. Quality of life of older patients with early-stage breast cancer receiving adjuvant chemotherapy: a companion study to cancer and leukemia group B 49907. *J Clin Oncol.* 2011; 29:1022–8. [PubMed: 21300923]
13. Cancer Therapy Evaluation Program, Common Toxicity Criteria (CTC) Version 2.0. 1999
14. Mantel N. Chi-Square Tests with One Degree of Freedom; Extensions of the Mantel-Haenszel Procedure. *Journal of the American Statistical Association.* 1963; 58:690–700.
15. Sakorafas GH, Peros G, Cataliotti L, et al. Lymphedema following axillary lymph node dissection for breast cancer. *Surg Oncol.* 2006; 15:153–65. [PubMed: 17187979]
16. Kotronoulas G, Kearney N, Maguire R, et al. What is the value of the routine use of patient-reported outcome measures toward improvement of patient outcomes, processes of care, and health service outcomes in cancer care? A systematic review of controlled trials. *J Clin Oncol.* 2014; 32:1480–501. [PubMed: 24711559]
17. Pedro-Guzman J. Managing Upper Extremity Dysfunction in Breast Cancer Survivors. 2016
18. Smoot B, Wong J, Cooper B, et al. Upper extremity impairments in women with or without lymphedema following breast cancer treatment. *J Cancer Surviv.* 2010; 4:167–78. [PubMed: 20373044]
19. Lucci A, McCall LM, Beitsch PD, et al. Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011. *J Clin Oncol.* 2007; 25:3657–63. [PubMed: 17485711]
20. Ashikaga T, Krag DN, Land SR, et al. Morbidity results from the NSABP B-32 trial comparing sentinel lymph node dissection versus axillary dissection. *J Surg Oncol.* 2010; 102:111–8. [PubMed: 20648579]
21. Land SR, Kopec JA, Julian TB, et al. Patient-reported outcomes in sentinel node-negative adjuvant breast cancer patients receiving sentinel-node biopsy or axillary dissection: National Surgical Adjuvant Breast and Bowel Project phase III protocol B-32. *J Clin Oncol.* 2010; 28:3929–36. [PubMed: 20679600]
22. Gnant M, Thomssen C, Harbeck N. St. Gallen/Vienna 2015: A Brief Summary of the Consensus Discussion. *Breast Care (Basel).* 2015; 10:124–30. [PubMed: 26195941]
23. Meretoja TJ, Leidenius MH, Tasmuth T, et al. Pain at 12 months after surgery for breast cancer. *Jama.* 2014; 311:90–2. [PubMed: 24381969]




Figure 1. Severity of EORTC QLQ-BR23 musculoskeletal events at baseline, 12 months, and 24 months in: arm/hand swelling (A), limited range of motion (B), breast swelling (C), breast sensitivity (D), breast pain, (E), and arm/shoulder pain (F).

Table 1

Baseline Patient Characteristics

Characteristic	Patients with Quality of Life information
Age (years)	N=321
Mean (SD)	72.0 (4.8)
Age 65-69	129 (40.2%)
Age 70-79	179 (55.8%)
Age 80+	13 (4.1%)
Gender	
Female	321 (100%)
Race	N=320
White	278 (86.9%)
Black	35 (10.9%)
Other	7 (2.2%)
Most Extensive Surgery	N=319
Breast Conservation Surgery	143 (44.8%)
Mastectomy	176 (55.2%)
Axillary Dissection	N=321
Yes	256 (79.8%)
No	65 (20.2%)
Radiation	N=300
Yes	161 (53.7%)
No	139 (46.3%)
Number of Examined Nodes	N=314
Mean (SD)	11.8 (7.3)
Range	0-32
Chemotherapy Type	N=321
AC (Doxorubicin and Cyclophosphamide)	99 (30.8%)
CMF (Cyclophosphamide, Methotrexate and Fluorouracil)	67 (20.9%)
Capecitabine	155 (48.3%)

Table 2

Patient-reported musculoskeletal events (MEs) over time

Number of patient-reported MEs experienced	Post-operative (N=321)	12 months (N=259)	24 months (N=240)
Mean (Median)	3.0 (3)	1.7 (2)	1.6 (1)
None	43 (13.4%)	72 (27.8%)	86 (35.8%)
1	31 (9.7%)	38 (14.7%)	40 (16.7%)
2	50 (15.6%)	58 (22.4%)	46 (19.2%)
3	68 (21.2%)	34 (13.1%)	39 (16.3%)
4	52 (16.2%)	30 (11.6%)	13 (5.4%)
5	44 (13.7%)	20 (7.7%)	12 (5.0%)
6	33 (10.3%)	7 (2.7%)	4 (1.7%)

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 3
Maximum grade of physician-reported lymphedema during the 24-month reporting period.

	Lymphedema Severity					
	None	Grade 1	Grade 2	Grade 3	p-value (any)	p-value (grade 3+)
For all patients (N=321)	297 (92.5%)	20 (6.2%)	4 (1.3%)	0 (0%)		
Vs treatment arm (N=321)						
CMF (Cyclophosphamide, Methotrexate and Fluorouracil) (N=67)	56 (88.6%)	9 (13.4%)	2 (3.0%)	0 (0%)	0.007	NA
AC (Doxorubicin and Cyclophosphamide) (N=99)	95 (96.0%)	4 (4.0%)	0 (0%)	0 (0%)		
Capecitabine (N=155)	146 (94.2%)	7 (4.5%)	2 (1.3%)	0 (0%)		
Vs Most Extensive Surgery (N=319)						
Breast Conserving Surgery (N=143)	134 (93.7%)	8 (5.6%)	1 (0.7%)	0 (0%)	0.453	NA
Full Mastectomy (N=176)	161 (91.5%)	12 (6.8%)	3 (1.7%)	0 (0%)		
Vs Axillary Dissection (N=321)						
No (N=65)	64 (98.5%)	1 (1.5%)	0 (0%)	0 (0%)	0.042	NA
Yes (N=256)	233 (91.0%)	19 (7.4%)	4 (1.6%)	0 (0%)		
Vs Radiation Therapy (N=300)						
No (N=139)	126 (90.7%)	11 (7.9%)	2 (1.4%)	0 (0%)	0.308	NA
Yes (N=161)	151 (93.8%)	9 (5.6%)	1 (0.6%)	0 (0%)		
Vs Number of Nodes Examined (N=314)						
0-3 (N=49)	47 (95.9%)	2 (4.1%)	0 (0%)	0 (0%)	0.023	NA
4-7 (N=58)	53 (100%)	0 (0%)	0 (0%)	0 (0%)		
8+ (N=212)	190 (89.6%)	18 (8.5%)	4 (1.9%)	0 (0%)		

Table 4

Lymphedema reported as an adverse event (AE) vs patient-reported swelling of arm and hand.

Time Frame (Patient Reported)	Lymphedema (AE)		p-value
	Yes	No	
Arm/Hand Swelling at Post-operative (N=321)			<0.001
Yes	13 (18.3%)	58 (81.7%)	
No	11 (4.4%)	239 (95.6%)	
Arm/Hand Swelling at 12 mo Post Op (N=259)			0.003
Yes	10 (18.5%)	44 (81.5%)	
No	12 (5.9%)	193 (94.1%)	
Arm/Hand Swelling at 24 mo Post Op (N=240)			<0.001
Yes	10 (21.3%)	37 (78.7%)	
No	6 (3.1%)	187 (96.9%)	

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 5

Arm function versus musculoskeletal events over time *

Rates with symptom	Post-operative	12 months	24 months
Vs LROM *	p<0.001	p=0.002	p<0.001
Poor Arm Function	111/186 (60%)	57/143 (39%)	38/133 (29%)
Normal Arm Function	51/130 (39%)	24/113 (21%)	11/105 (10%)
Vs Breast Sensitivity	p=0.004	p=0.038	p=0.164
Poor Arm Function	122/186 (66%)	69/142 (46%)	45/133 (34%)
Normal Arm Function	64/130 (49%)	38/113 (34%)	27/105 (26%)
Vs Breast Swelling	p=0.352	p=0.018	p=0.343
Poor Arm Function	90/186 (48%)	24/141 (17%)	15/133 (11%)
Normal Arm Function	56/130 (43%)	8/113 (7%)	8/105 (8%)
Vs Arm/Shoulder Pain	p=0.078	p=0.005	p=0.001
Poor Arm Function	126/187 (67%)	81/143 (57%)	70/133 (53%)
Normal Arm Function	75/130 (58%)	44/113 (39%)	33/105 (31%)
Vs Breast Pain	p<0.001	p=0.266	p=0.065
Poor Arm Function	126/186 (68%)	72/143 (50%)	56/133 (42%)
Normal Arm Function	60/128 (47%)	49/113 (44%)	32/105 (30%)
Vs Arm/Hand Swelling	P=0.260	p=0.136	p=0.060
Poor Arm Function	46/187 (25%)	35/143 (24%)	32/133 (24%)
Normal Arm Function	25/130 (19%)	19/113 (17%)	15/105 (14%)

* For example, at the post-operative time point, patients with poor arm function at baseline had limited range of motion (LROM) 60% of the time compared to 39% for those with normal arm function